Leukoderma associated with Sézary syndrome: A rare presentation

Journal of the American Academy of Dermatology

Volumn 49, Issue 5 SUPPL., 2003, Pages 247-249

  Tang, Mark ^a   Tan, Suat Hoon ^a   Lim, Lay Cheng ^b  

^a NATIONAL SKIN CENTRE   (Singapore)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ELECTRON BEAM; ERYTHRODERMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKODERMA; MALE; MELANOCYTE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; RADIATION DOSE; SEZARY SYNDROME; SKIN BIOPSY; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME;

EID: 0142244863     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(03)00473-0     Document Type: Article

References (15)

1. Bogen SA, Pelley D, Charif M, McCusker M, Koh H, Foss F, et al. Immunophenotypic identification of Sézary cells in peripheral blood. Am J Clin Pathol 1996;106:739-48.
2. Bergengo MG, Quaglino P, Novelli M, Cappello N, Doveil GC, Lisa F, et al. Prognostic factors in Sézary syndrome: a multivariate analysis of clinical, hematological and immunological features. Ann Oncol 1998;9:857-63.
3. Dalloul A, Laroche L, Bagot M, Djavad Mossalayi M, Fourcade C, Thacker DJ, et al. Interleukin-7 is a growth factor for Sézary lymphoma cells. J Clin Invest 1992;90:1054-60.
4. - immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 1996;35:404-10.
5. Yagi H, Tokura Y, Furukawa F, Takigawa M. CD 7-positive Sézary syndrome with a Th1 cytokine profile. J Am Acad Dermatol 1996;34:368-74.
6. Bouloc A, Grange F, Delfau-Larue MH, Dieng MT, Tortel MC, Favril M, et al. Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: four cases. Br J Dermatol 2000;143:832-6.
7. Alcalay J, David M, Shohat B, Sandbank M. Generalized vitiligo following Sézary syndrome. Br J Dermatol 1997;116:851-5.
8. Lerner AB, Nordlund JJ. Vitiligo. What is it? Is it important? JAMA 1978;239:1183-7.
9. Bolognia JL, Pawelek JM. Biology of hypopigmentation. J Am Acad Dermatol 1988;19:217-25.
10. Todes-Taylor N, Abel EA, Cox AJ. The occurrence of vitiligo after psoralens and ultraviolet A therapy. J Am Acad Dermatol 1983;9:526-32.
11. Tan E, Tay YK, Giam YC. Profile and outcome of childhood mycosis fungoides in Singapore. Paediatr Dermatol 2000;7:352-6.
12. Lambroza E, Cohen SR, Phelps R, Lebwohl M, Braverman IM, DiCostanzo D. Hypopigmented variant of mycosis fungoides: demography, histopathology and treatment of seven cases. J Am Acad Dermatol 1995;32:987-93.
13. Akaraphanth R, Douglass MC, Lim HW. Hypopigmented mycosis fungoides: treatment and a 6 1/2-year follow-up of 9 patients. J Am Acad Dermatol 2000;42:33-9.
14. Castanet J, Ortonne JP. Physiopathology of vitiligo. Clin Dermatol 1997;15:845-51.
15. Fraser-Andrews EA, Woolford AJ, Russell-Jones R, Seed PT, Whittaker SJ. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000;114:117-21.